Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Equilibrative nucleobase transporter 1 (SLC43A3) is a member of the solute carrier family 43 and functions as a sodium-independent, purine-selective nucleobase transporter. It mediates the equilibrative transport of extracellular purine bases, such as adenine, guanine, and hypoxanthine, across plasma membranes, particularly in the liver and lung[2][3]. SLC43A3 is also able to transport the purine analog drug 6-mercaptopurine[3]. It does not require sodium or protons for its transport activity and is not involved in nucleoside transport[2]. Beyond nucleobase transport, SLC43A3 may play a regulatory role in fatty acid transport in adipocytes, possibly acting as a positive regulator of fatty acid efflux and a negative regulator of fatty acid uptake[1][3]. SLC43A3 may be relevant in diseases involving purine metabolism and transport, and is also associated with the cellular pharmacokinetics of purine analog drugs like 6-mercaptopurine[3].
Facilitates influx and efflux of purine nucleobases and the purine analog drug 6-mercaptopurine, sodium-independent equilibrative transport mechanism
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Equilibrative nucleobase transporter 1 (SLC43A3).